

# Alliance

Rebecca Heist  
Member, Alliance Respiratory Committee  
TACT General Assembly  
1 June 2016

## Our Vision

The **Alliance for Clinical Trials in Oncology** seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer.

## Our Mission

The mission of the **Alliance for Clinical Trials in Oncology** is to reduce the impact of cancer by:

- Conducting high quality multidisciplinary cancer control, prevention, and treatment trials that engage a comprehensive research network
- Furthering our understanding of the biological basis of the cancer process and its treatment, from discovery, to validation, to clinical practice
- Providing a scientific and operational infrastructure for innovative clinical and translational research in the academic and community settings




## Background of Alliance

- Part of a clinical trials network sponsored by the National Cancer Institute (NCI)
- Formed by the merger of three cooperative groups: American College of Surgeons Oncology Group (ACOSOG), Cancer and Leukemia Group B (CALGB), and North Central Cancer Treatment Group (NCCTG) in response to IOM call to strengthen and streamline operations among NCI clinical trials cooperative group programs
- One of network groups that comprise the NCI National Clinical Trials Network (NCTN)

## Structure

- The Alliance for Clinical Trials in Oncology is governed by a Board of Directors and Executive Committee and led by a Group Chair and Principal Investigator.
- The Alliance is organized into five programs, each led by a Co-Principal Investigator.
  - ▶ Statistics and Data Management
  - ▶ Central Protocol Operations
  - ▶ Translational Research
  - ▶ Cancer Control
  - ▶ American College of Surgeons Clinical Research
- The Alliance comprises nearly 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada. Programs include:
- The Alliance Respiratory Committee is charged with clinical trial development in thoracic cancers

# Main Member Institutions



# Publications of Respiratory Committee

01/2015 – 05/2016

STATUS

No.

---

Manuscripts

-- Published/Accepted/In Press

15

-- Submitted/In Preparation

10

Abstracts

4

# Examples of Active Respiratory Studies

## **ALLIANCE A151216**

### **Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)**

<b>Study Chair:</b>	<b>G. Oxnard</b>
<b>Activated:</b>	<b>08/18/2014</b>
<b># Sites Opened*:</b>	<b>1074</b>



## **ALLIANCE A081105**

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected EGFR Mutant NSCLC

Study Chair:	R. Govindan
Activated:	08/18/2014
# Sites Opened*:	1074

## **ECOG E4512**

A Phase III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib Versus Placebo for Patients with Tumors Harboring ALK Fusion Protein

Activation Date:

08/18/2014

## AFT 07

Phase I Dose Escalation and Phase II Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III NSCLC

Study Chairs:	J. Salama / T. Stinchcombe
Activated:	12/29/2014
# Sites Opened (Phase I):	12
# Sites Opened (Phase II):	60-75

## AFT 09

Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition with Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients with Previously Untreated Stage IV NCSLC

Study Chairs:	T. Hensing
Activated:	03/17/2016
# Sites Opened:	30

## **ACCRU RC1126**

A Randomized Phase II Trial of Erlotinib Alone or in Combination with Bevacizumab in Patients with Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Study Chair:	T. Stinchcombe
Activated:	03/16/2012
# Sites Opened:	19

## **CALGB 30901**

Randomized Phase II Study Of Maint. Pemetrexed VS  
Observation For Patients With Malignant Pleural Meso W/o  
Progression After First-Line Chemotherapy

Study Chair:	A. Dudek
Activated:	04/15/2010
# CALGB / CTSU Sites Open:	185 / 12

# Examples of Intergroup Active Studies

## **Lung-MAP SWOG 1400**

Phase II/III Biomarker-Driven Master Protocol for 2nd Line  
Therapy of Squamous Cell Lung Cancer

Alliance Co-Chair:

M. Socinski

Activation Date:

06/16/2014

Primary Objective: To establish a NCTN mechanism for genomically screening large but homogeneous cancer populations and subsequently assigning and accruing simultaneously to a multi-sub-study "Master Protocol."